India, May 15 -- India has received its first seven-minute injectable immunotherapy treatment for lung cancer, marking a major advancement in cancer care and patient convenience. Swiss pharma giant Roche has launched the subcutaneous version of its immunotherapy drug Tecentriq, also known as atezolizumab, in the Indian market.

Unlike traditional intravenous immunotherapy that can take several hours, the new injection can be administered under the skin in just seven minutes, significantly reducing hospital time for patients.

The treatment is designed for patients suffering from non-small cell lung cancer (NSCLC), which accounts for the majority of lung cancer cases diagnosed in India every year. However, doctors say the therapy is suitab...